# Lumos Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lumos-pharma

- Industry: Biotechnology
- Headquarters: Austin, US
- Website: www.lumos-pharma.com
- Total disclosed funding: $47M
- Latest round: Series B (Apr 4, 2016)
- Investors on record: 6

## About

Lumos Pharma, Inc. is a biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases, particularly focusing on Pediatric Growth Hormone Deficiency (PGHD).Founded in 1999 and headquartered in Austin, US, Lumos Pharma, Inc. specializes in treatments for rare pediatric diseases. The company underwent a merger with NewLink Genetics Corporation in September 2019, transitioning into a public company. In July 2020, Lumos Pharma, Inc. secured a Trade Sale, selling a Priority Review Voucher for USD 60 mn to Merck & Co., Inc. This transaction marks a significant milestone in the company's funding journey, raising a total of USD 60 mn.Lumos Pharma focuses primarily on developing therapeutics for rare diseases, with a strong emphasis on Pediatric Growth Hormone Deficiency (PGHD). Their flagship product, LUM-201, addresses challenges faced by children suffering from PGHD, which can lead to significant growth retardation, short stature, and delayed maturation. The company’s products are primarily targeted at pediatric patients, their families, and healthcare providers specializing in endocrinology and pediatric care. Lumos Pharma's innovative solutions are being developed for markets in North America and Europe, where there is a substantial clientele of healthcare facilities and professionals dedicated to treating rare diseases.Lumos Pharma reported a revenue of USD 2,051 mn for the most recent year, with an EBITDA of USD 35,873 mn. The company’s revenue structure is built around partnerships with healthcare providers and institutions involved in treating rare pediatric diseases through structured agreements for purchasing their therapeutic treatments on a per-case basis.Lumos Pharma plans to expand its product offerings, with a focus on launching LUM-201 across more markets by mid-2023. The company aims to penetrate additional geographic regions in North America and Europe, facilitated by the recent funding from Merck & Co., Inc., which will support further clinical trials and market entry strategies. The recent Trade Sale deal is expected to bolster their financial position, allowing them to enhance product development and outreach initiatives.

## Funding rounds

- Series B, Apr 4, 2016, $34M — New Enterprise Associates, Clarus Ventures, Sante Ventures, UCB S.A., Roche Venture Fund, Deerfield Management
- Series A, Apr 30, 2015, $6.5M — New Enterprise Associates, Sante Ventures
- Series A, Jan 24, 2014, $6.5M — New Enterprise Associates, Sante Ventures

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B
- Sante Ventures (https://capitalatlas.ai/funds/sante-ventures) — Series A, Series B
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series B
- UCB S.A. — Series B
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series B
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series B